West Pharmaceutical Services, Inc. $WST Stock Position Lifted by Merit Financial Group LLC

Merit Financial Group LLC lifted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 164.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,573 shares of the medical instruments supplier’s stock after purchasing an additional 3,463 shares during the quarter. Merit Financial Group LLC’s holdings in West Pharmaceutical Services were worth $1,533,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Holocene Advisors LP bought a new position in shares of West Pharmaceutical Services in the third quarter worth $49,085,000. Rockland Trust Co. grew its stake in shares of West Pharmaceutical Services by 6.5% in the third quarter. Rockland Trust Co. now owns 83,066 shares of the medical instruments supplier’s stock worth $21,791,000 after purchasing an additional 5,087 shares in the last quarter. Nordea Investment Management AB lifted its holdings in shares of West Pharmaceutical Services by 42.7% in the fourth quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier’s stock valued at $4,122,000 after buying an additional 4,477 shares during the period. Cibc World Market Inc. lifted its holdings in shares of West Pharmaceutical Services by 300.0% in the third quarter. Cibc World Market Inc. now owns 18,586 shares of the medical instruments supplier’s stock valued at $4,876,000 after buying an additional 13,940 shares during the period. Finally, DAVENPORT & Co LLC lifted its holdings in shares of West Pharmaceutical Services by 559.8% in the fourth quarter. DAVENPORT & Co LLC now owns 9,521 shares of the medical instruments supplier’s stock valued at $2,620,000 after buying an additional 8,078 shares during the period. Institutional investors own 93.90% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on WST shares. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. UBS Group restated a “buy” rating and issued a $340.00 price objective on shares of West Pharmaceutical Services in a report on Friday, February 13th. Evercore cut their price objective on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating for the company in a report on Tuesday, February 3rd. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 14th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $315.00 price objective on shares of West Pharmaceutical Services in a report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Moderate Buy” and a consensus target price of $315.67.

West Pharmaceutical Services Trading Down 0.0%

Shares of West Pharmaceutical Services stock opened at $274.59 on Thursday. West Pharmaceutical Services, Inc. has a fifty-two week low of $199.89 and a fifty-two week high of $322.34. The firm has a market cap of $19.79 billion, a price-to-earnings ratio of 40.44, a price-to-earnings-growth ratio of 2.92 and a beta of 1.15. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $250.67 and a 200-day simple moving average of $261.77.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, beating the consensus estimate of $1.83 by $0.21. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The business had revenue of $805.00 million during the quarter, compared to the consensus estimate of $795.70 million. During the same period in the prior year, the business posted $1.82 earnings per share. West Pharmaceutical Services’s revenue was up 7.5% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. On average, equities analysts forecast that West Pharmaceutical Services, Inc. will post 7.91 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th will be paid a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio is currently 12.96%.

West Pharmaceutical Services announced that its Board of Directors has initiated a stock repurchase program on Tuesday, February 17th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical instruments supplier to purchase up to 5.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.